NattoPharma: 4th Quarter 2015 earnings release

Please find attached the 4th Quarter 2015 Earnings Release

Highlights for the quarter,

  • Record quarter revenue at NOK 11,0 million
  • Appointed a new management team, lead by the new CEO Daniel H. Rosenbaum
  • Completed an internal restructuring as the company shifts its focus from research to commercialization;
  • Successfully transitioned to the commercial phase in the scale-up of the synthetic PURE production
  • Conducted the first industry educational seminar during the Supply Side West international industry supplement show in Las Vegas, Nevada, USA

A presentation will be held via webcast by CEO Daniel H. Rosenbaum and CFO Kjetil Ramsøy at 10 am CET, Friday 26thFebruary, followed by a Q&A session directly thereafter.

Please follow the below link to join the webcast;

For more information, please contact:

Kjetil Ramsøy

CFO, NattoPharma

Mobil: +47 906 12 943


This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.

About NattoPharma and MenaQ7®

NattoPharma ASA, based in Norway, is the world's leader in vitamin K2 R&D. NattoPharma is the exclusive international supplier of MenaQ7® Vitamin K2 as MK-7, the best documented, commercially available Vitamin K2 as MK-7 with guaranteed actives and stability, clinical substantiation, and international patents granted and pending. The company has a multi-year research and development program to substantiate and discover the health benefits of vitamin K2 for applications in the marketplace for functional food and dietary supplements. With a global presence, the company established its North American subsidiary, NattoPharma USA, Inc., in Metuchen, NJ.

For more information, visit or


Om oss

NattoPharma utvikler og selger vitamin K2 som blant annet virker forebyggende mot osteoporose og hjerte- og karsykdommer. Selskapet bygger konkurransefortrinn med klinisk forskning, patentbeskyttelser og -rettigheter, samt sterk salgs- og markedssatsning. NattoPharma har enerett til å selge og markedsføre merkevaren MenaQ7® (Vitamin K2 /MK-7) globalt og tilbyr per i dag sine produkter som ingrediens i kosttilskudd, functional food og medical


Dokumenter og linker